Daye Secures $10M Series A to Revolutionize Women’s Health and Close the Gender Gap

Daye, a pioneering female-founded gynae health start-up on a mission to close the gender health gap, is thrilled to announce the successful raising of $10,000,000 in its latest funding round.

This landmark investment underlines the confidence that investors have in Daye’s innovative approach to tackling long-standing challenges in women’s health.

Starting with the invention of the world’s first pain-relieving tampon, Daye has already made a significant impact by helping over 75,000 women and AFAB individuals kick period pain to the curb.

Building on that solid foundation, the company launched its second-generation tampon, which now enables the at-home detection of vaginal infections, STIs, and HPV, thereby transforming personal health monitoring and early intervention practices.

With new funding in hand, Daye is poised to accelerate the development of solutions for other under-served gynae health conditions, including endometriosis, PCOS, and menopause.

Over the next five years, the company envisions building a comprehensive ecosystem where every woman can easily understand, monitor, and improve her health directly from her smartphone.

By integrating cutting-edge technology with expert medical insights, Daye aims to empower women globally through accessible, personalized care.

This substantial infusion of capital will not only fuel research and development but also support robust clinical trials and strategic partnerships, ensuring that Daye continues to lead the charge in revolutionizing women’s health.

Investors, customers, and partners alike are eagerly watching as Daye continues to redefine what personalized, proactive healthcare can do for women everywhere, paving the way for a future where equitable health outcomes are within everyone’s reach.